Keros Therapeutics Inc (KROS)

06:44 AM

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March - MarketBeat

06:44 AM

Apr 13, 2026

Understanding the Setup: (KROS) and Scalable Risk - Stock Traders Daily

Apr 13, 2026

Apr 13, 2026

Wall Street Recap: Can Keros Therapeutics Inc weather a recessionWeekly Gains Report & Risk Managed Investment Strategies - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN

Apr 12, 2026

Apr 10, 2026

Wedbush Maintains Keros Therapeutics (KROS) Neutral Recommendation - MSN

Apr 10, 2026

Apr 08, 2026

KROS SEC FilingsKeros Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 08, 2026

Apr 07, 2026

BlackRock (KROS) reports 1.99M-share, 10.1% passive stake in Keros Therapeutics - Stock Titan

Apr 07, 2026

Apr 07, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts - MarketBeat

Apr 07, 2026

Apr 06, 2026

Keros Therapeutics (KROS) CEO exercises options for 55,000 shares - Stock Titan

Apr 06, 2026

Apr 06, 2026

JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS - MarketBeat

Apr 06, 2026

Apr 06, 2026

Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC - MarketBeat

Apr 06, 2026

Apr 06, 2026

Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN

Apr 06, 2026

Apr 03, 2026

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report? - Yahoo Finance

Apr 03, 2026

Apr 02, 2026

The Technical Signals Behind (KROS) That Institutions Follow - Stock Traders Daily

Apr 02, 2026

Apr 01, 2026

Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? - MSN

Apr 01, 2026

Apr 01, 2026

KROS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Apr 01, 2026

Mar 31, 2026

[144] Keros Therapeutics, Inc. SEC Filing - Stock Titan

Mar 31, 2026

Mar 30, 2026

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - qz.com

Mar 30, 2026

Mar 27, 2026

Keros Therapeutics (KROS) awards 80,000 stock options to Chief Legal Officer - Stock Titan

Mar 27, 2026

Mar 27, 2026

Vanguard disaggregates holdings; reports 0 KROS shares (KROS) - Stock Titan

Mar 27, 2026

Mar 25, 2026

Fed Meeting: What are Keros Therapeutics Incs technical support levels2026 Dividend Review & Fast Gain Swing Alerts - baoquankhu1.vn

Mar 25, 2026

Mar 25, 2026

KROS stock: What to know about Rinvatercept in DMD - MSN

Mar 25, 2026

Mar 25, 2026

Chart Watch: What is Keros Therapeutics Incs P E ratio telling us2026 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn

Mar 25, 2026

Mar 25, 2026

Institution Moves: Can Keros Therapeutics Inc weather a recessionM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn

Mar 25, 2026

Mar 25, 2026

Published on: 2026-03-25 15:00:50 - baoquankhu1.vn

Mar 25, 2026

Mar 23, 2026

Pulmonary Arterial Hypertension Market: Expanding Revenue Landscape to 2034 – DelveInsight | Merck, Janssen Pharma, Aerovate Therapeutics, Novartis, Insmed Inc, Chugai Pharma, Keros Therapeutics - Barchart.com

Mar 23, 2026

Mar 22, 2026

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from S&P Biotechnology Select Industry Index - MarketScreener

Mar 22, 2026

Mar 22, 2026

Precision Trading with Keros Therapeutics Inc. (KROS) Risk Zones - Stock Traders Daily

Mar 22, 2026

Mar 21, 2026

Quarterly Trades: Is now the right time to enter Keros Therapeutics Inc2026 Price Action Summary & Real-Time Volume Analysis - baoquankhu1.vn

Mar 21, 2026

Mar 21, 2026

Block Trades: Will RIVN benefit from current market trendsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 18, 2026

Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN

Mar 18, 2026

Mar 18, 2026

Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget

Mar 17, 2026

Mar 17, 2026

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - sharewise.com

Mar 17, 2026

Mar 17, 2026

KROS Stock: Key Information on Rinvatercept for DMD - Bitget

Mar 17, 2026

Mar 17, 2026

KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget

Mar 17, 2026

Mar 17, 2026

KROS Stock: What to Know About Rinvatercept in DMD - Yahoo Finance

Mar 17, 2026

Mar 16, 2026

KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI

Mar 16, 2026

Mar 16, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat

Mar 16, 2026

Mar 13, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

Mar 13, 2026

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart

Mar 12, 2026

Mar 12, 2026

Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com

Mar 12, 2026

Mar 11, 2026

Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan

Mar 11, 2026

Mar 11, 2026

Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan

Mar 11, 2026